title: [Assessment of immunotoxicity of irinotecan determined by the novel method, by which productivity of TNF-alpha from whole blood is stimulated by lipopolysaccharide].
abstract: Irinotecan hydrochloride shows much different responses in each patient, and it has severe adverse effects. Therefore, a sensitive marker for the side effect of irinotecan on immunotoxicity may be able to prevent the severe complications by the early detection. We have recently developed a method to assess the immunotoxicity by measuring the productivity of TNF-alpha from whole blood containing monocytes when stimulated by lipopolysaccharide. By using this method, the effects of continuous low-dose irinotecan therapy on immunotoxicity were assessed in 10 patients with advanced gastric or colon cancer. When compared this method with the others such as white blood cell count, lymphocyte blastoid transformation by phytohem agglutinin (PHA), and natural killer cell activity in terms of the sensitivity, immunotoxicity by this method was found earlier than the other methods. Because our original method is easy to perform and sensitive as compared to the conventional methods, it can be widely used as one of the laboratory tests useful for patients treated with immunosuppressive agents.
authors.affiliation: Department of Surgery, Kansai Medical University, Moriguchi 570-8507.
authors.forename: Yusai
authors.initials: Y
authors.lastname: Kawaguchi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Araki
authors.forename: Akihiko
authors.initials: A
authors.lastname: Nakagawa
authors.forename: Morihiko
authors.initials: M
authors.lastname: Ishizaki
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Kamiyama
authors.forename: Noriko
authors.initials: N
authors.lastname: Nishimura
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Komiyama
authors.forename: Hakuo
authors.initials: H
authors.lastname: Takahashi
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D001769:Blood / Q000276:immunology / Q000378:metabolism; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D003110:Colonic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D006801:Humans; D007159:Immunologic Tests / Q000379:methods*; D007262:Infusions, Intravenous; D000077146:Irinotecan; D008070:Lipopolysaccharides / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009000:Monocytes; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000096:biosynthesis*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D015415:Biomarkers; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D000077146:Irinotecan; D002166:Camptothecin